Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2019

View Archived Issues

LNC helps TNBC go AWOL

Gilead initiates phase I study of GS-1423 in advanced solid tumors

Inhibiting CCL24 with CM-101 reduces fibrosis and inflammation in systemic sclerosis

Luspatercept MOA: Up for grabs?

Increased clotting contributes to cardiovascular risk in HIV-infected individuals

Bayer, Deutsches Krebsforschungszentrum patent aryl hydrocarbon receptor antagonists

Collaborative Medicinal Development describes ferroptosis inhibitors

New PPAR agonists identified at Sichuan Kelun-Biotech Biopharmaceutical

Positive 6-month results from phase II open-label study of ATI-502 in androgenetic alopecia

Regeneron Pharmaceuticals initiates phase II study of REGN-5069 in osteoarthritis of the knee

Ribomic presents positive topline results from phase I/IIa SUSHI study of RBM-007 in wet AMD

Avelumab plus axitinib combination demonstrates antitumor activity in first-line HCC

Phase I results for venetoclax plus high-dose cytarabine in children with relapsed/refractory AML

New PRMT5 inhibitors presented by Jubilant Biosys

Kyoto Pharmaceutical Industries discovers albumin-binding prodrugs

CB-5064 analogues for weight and fat loss tested in vitro and in vivo

Netakimab safe and effective in spondyloarthritis: data from the phase III ASTERA trial

Repeat dosing of KZR-616 is well tolerated in patients with systemic lupus erythematosus

RNF213 gene variant found to cause pulmonary arterial hypertension with poor prognosis

Xeris reports promising data from phase III study of ready-to-use glucagon

FDA approves Victoza for type 2 diabetes in children and adolescents

BI-765063 begins first-in-human study in advanced solid tumors

CRV-431 decreases fibrosis and key biomarkers of liver disease in experimental model

PB-2452 reverses ticagrelor antiplatelet activity in older and elderly patients in phase IIa trial

European approval of Lynparza as first-line maintenance treatment for BRCAm advanced ovarian cancer

Rozlytrek approved in Japan for NTRK fusion-positive, advanced recurrent solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...